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Abstract
Background: Helicobacter pylori is an important pathogen of human gastric mucosa. Antibiotic resistance, especially resistance to
clarithromycin is a major factor for treatment failure of H. pylori infections. The main mechanism of clarithromycin resistance in
these bacteria is related to point mutations in three different locations of 23S rRNA gene.
Objectives: The aims of this study were to evaluate the resistance rate to clarithromycin among local H. pylori isolates by the E-test
method and to determine the profile of point mutation in 23S rRNA by real-time polymerase chain reaction (PCR) method.
Patients andMethods: Eighty biopsy samples were collected from dyspeptic patients by endoscopy during 2011 - 2012. All samples
were homogenized immediately and cultured on supplemented brucella blood agar and incubated under microaerophilic condi-
tions. Further biochemical tests and ureC gene PCR was done for H. pylori confirmation. The H. pylori OC1096 strain was used as the
control strain, simultaneously. Frequency of clarithromycin resistance was determined by the E-test method based on the clinical
and laboratory standard institute (CLSI) standards. Point mutation profile was determined by real-time PCR and further analysis of
melting curve, amplicon sequencing was done continuously.
Results: From 80 biopsy samples, 20 positive H. pylori isolates were detected and confirmed by biochemical tests and PCR method.
Overall, 21.7% of the H. pylori isolates, showed clarithromycin resistance phenotype by use of the E-test. Also, the minimal inhibitory
concentration of clarithromycin was determined as≥ 0.5 mg/L by the E-test method. Only point mutation in the location of A2143G
with melting temperature of 54.7°C was observed in all resistant isolates.
Conclusions: This study showed that the frequency of H. pylori clarithromycin resistance in Iran is relatively high. Since clar-
ithromycin is not commonly used in Iran for H. pylori eradication, the high rate of resistance could be related to cross-reactivity
between other macrolides. Therefore, macrolide antibiotics must be prescribed with precaution in any case of treatment other
than H. pylori infections. All resistant isolates showed A2143G mutation in 23S rRNA as the dominant pattern of point mutation at
least in Tehran H. pylori isolates.
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1. Background
Helicobacter pylori is a Gram-negative, microaerophilic
spiral bacteria that colonize in gastric epithelial tissue and
mucus of half of the worlds and 80% of the Iranian popu-
lation (1, 2). The prevalence of H. pylori infection varies all
over the world based on geographic area, age, race and san-
itary conditions. Helicobacter pylori are mainly acquired in
childhood due to lack of proper hygiene (3). Infection with
H. pylori is associated with some gastrointestinal disor-
ders, including chronic gastritis, peptic ulceration, gastric
mucosa-associated lymphoid tissue lymphoma, intestinal
metaplasia and gastric cancer (4). Despite the suscepti-
bility of H. pylori to many antibiotics in vitro, its eradica-
tion is difficult in vivo. This is thought to be due to inac-
tivation of antibiotics in acidic environments of the gas-
tric mucosa (5). Commonly, triple therapy including a pro-
ton pump inhibitor (PPI) (omeprazole or pantoprazole)
together with two antibiotics such as clarithromycin and
metronidazole or amoxicillin is used for treating of H. py-
lori infection. Also, fluoroquinolones, nitrofurans and ri-
famycins are used as alternatives (6). Clarithromycin has a
key role in triple therapy.
Clarithromycin (6-O-methyl erythromycin) is a
macrolide antibiotic that inhibits protein synthesis of
bacteria by binding to the 50s subunit of bacterial ri-
bosome. Acid stability and good absorption in gastric
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mucus layer make it a good choice for H. pylori eradication
in comparison to other macrolides (7). Unfortunately,
appearance and increasing resistance to clarithromycin
among H. pylori isolates has been reported all over the
world (8). This phenomenon decreases the efficacy of H.
pylori eradication rate, for example in a study, the eradica-
tion rate for clarithromycin-susceptible isolates was 90%,
whereas it was 36% for clarithromycin-resistant isolates
(9). Also, resistance to clarithromycin shows geographical
variation (8). For instance the rate of clarithromycin
resistance that was reported in the north of Iran (Sari) is
greater than once reported in south (Shiraz) of this coun-
try (10). Therefore, before clarithromycin prescription in
Helicobacter pylori treatment, determination of the local
susceptibility pattern is necessary in any region.
This is possible by approved antibiotic susceptibility
testing (AST) methods against bacteria, such as agar dilu-
tion, E-test and disk diffusion. Agar dilution is considered
as the gold standard method, yet it is highly laborious and
expensive. Therefore, agar dilution could be replaced by
E-test or disk diffusion methods (11, 12). E-test is a simple
and easy test for determining minimal inhibitory concen-
tration (MIC) of a variety of antibiotics, however it is more
expensive. Molecular mechanism of clarithromycin resis-
tance in H. pylori, is related to point mutations in 23S rRNA,
which can effect protein synthesis.
The three most popular point mutations in 23S rRNA
are A to G transition at position 2142 (A2142G) or 2143
(A2143G) and less frequently, A2142C (13). Several molecular
techniques have been developed for the detection of clar-
ithromycin resistance in H. pylori including, restriction
fragment length polymorphism (RFLP), 3’-mismatch re-
verse primer PCR method (3M-PCR), PCR-oligonucleotide
ligation assay (OLA), fluorescent in situ hybridization
(FISH), PCR-preferential homoduplex formation assay
(PHFA) and real-time PCR hybridization assay (5). Among
these methods, real-time PCR is known as a simple, rapid
and reproducible method for the detection of mutations
(14). Many investigators used this method for detection
of different locations of point mutations in bacterial or
eukaryotic genome (15, 16). For instance, Oleastro et al. (17)
used real-time the PCR assay to detect point mutations in
23S rRNA of H. pylori and described this method as a rapid,
accurate and reliable method for this goal.
2. Objectives
The aims of this study were the determination of the
resistance rate to clarithromycin among local H. pylori iso-
lates by the E-test method at first and further determina-
tion of the point mutation profile by analysis of the melt-
ing curve by the real-time PCR method.
3. Patients andMethods
3.1. Patients and Bacterial Strains
The sample size (80 biopsies) was determined based on
the frequency of resistance to clarithromycin among H. py-
lori isolates (28%) as reported by the study of Malekzadeh
et al. (18). Continuously, from patients with gastrointesti-
nal disorders, who were candidates for endoscopy at Mi-
lad and Fayyazbakhsh hospitals (Tehran and Karaj, Iran),
three biopsies were taken during 2011 - 2012. One of them
was used for rapid urease test and the two remaining were
transported to microbial laboratory in Stuart’s transport
medium (Merck, Germany) as soon as possible (less than
five hours). Biopsies were homogenized, cultured in se-
lective medium, brucella blood agar (Merck, Germany), in-
cluding vancomycin (Sigma-Aldrich, USA), trimethoprim
sulfametoxazol (Sigma-Aldrich, USA), polymyxin B (Sigma-
Aldrich, USA) antibiotics, supplemented with sodium
pyruvate (Sigma-Aldrich, USA) and ferrous sulfate (Sigma-
Aldrich, USA), and then incubated under microaerophilic
conditions using the gaspak incubation method (113829
Anaerocult® A, Merck, Type C Gas-Pak) for 48 - 72 hours
at 37°C. After appearance of colonies, identification tests
including Gram staining, catalase and oxidase tests were
done. Also, H. pylori isolates were confirmed by PCR ampli-
fication of ureC gene after DNA extraction with the boiling
method. Primer sequences (Bioneer company, Korea) are
showed in Table 1 (17). This research was accepted by the
ethics committee of Shahid Beheshti University of Medical
Sciences (SBMU) at 13 Jan 2010.
Table 1. The Primers and Probes Used in This Study
Primer/Probe Name Sequence Hybridization
Region
ureC (Bioneer, Korea) 5’-
GGATAAGCTTTTAGGGGTGTTAGGGG-
3’
5’-
GCTTACTTTCTAACACTAACGCGC-
3’
HPY-S, HPY-A
(Bioneer, Korea)
5’-
AGGTTAAGAGGATGCGTCAGTC-
3’
5’-
CGCATGATATTCCCATTAGCAGT-
3’
Sensor probe, Anchor
probe (Bioneer,
Korea)
5’Cy5-
GGCAAGACGGAAAGACC-
3’
2504 - 2520
TGTAGTGGAGGTGAAAATTCCTCCTACCC-
3’FAM
2473 - 2501
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3.2. Antibiotic Susceptibility Test
Resistance to clarithromycin was tested with epsilome-
ter strips (E-test, Lioflichem Co, Denmark), according to the
CLSI protocol and manufacturer’s instructions. Fresh H. py-
lori isolates were subcultured on selective brucella blood
agar (Merck, Germany) for 72 hours. Bacterial suspension
equivalent to McFarland turbidity standard three were pre-
pared and spread on non-selective brucella blood agar
plates (without antibiotics). After drying of plates, a single
E-test strip was placed on them. The plates were incubated
under microaerophilic conditions (116275/Anaerocult® C
Merck, Germany) at 37°C. After 72 hours, susceptibility and
MIC of the isolates were determined, simultaneously. The
H. pylori OC1096 strain (bestowed by research center for
gastroenterology and hepatology disease, Shahid Beheshti
University of Medical Sciences Tehran, Iran) was used as a
control isolate. The sensitive (S) and resistant (R) isolates
were determined based on the MIC as follow; S≤0.25 mg/L
and R≥ 0.5 mg/L.
3.3. DNA Extraction
DNA extraction was done by the boiling method (19,
20). The concentration of extracted DNA was determined
after optical density (OD) detection by the nanodrop in-
strument (Biointellectic TM Nano 200, Canada).
3.4. UreC Amplification
For confirmation of detected colonies as H. pylori, exis-
tence of ureC gene was done by the PCR method. The PCR
reaction was carried out in a thermal cycler (Eppendorph
Master cycle, Germany) as follow; 35 amplification cycles
consisting of a denaturation step at 94°C for one minute,
an annealing step at 54°C for one minute and extension
step at 72°C for one minute, which were performed after
a pre-denaturation of the target DNA at 94°C for four min-
utes. The final cycle was an extension step at 72°C for five
minutes.
3.5. Detection of 23S rRNA Gene Mutations of H. pylori by Real-
Time-Polymerase Chain Reaction
The molecular mechanism of clarithromycin resis-
tance was investigated by the real time-PCR method and
determination of the melting temperature. Real-time PCR
was performed on DNA extracted from H. pylori isolates in
Rotor-Gene 6,000 (Corbett). A primer pair (HPY-S and HPY-
A, Table 1) was used to amplify the 267 bp fragment of 23s
RNA gene. Also, sensor and anchor probes were used to de-
termine point mutations. Real-time PCR assays were per-
formed as follows: an initial denaturation step at 95°C for
10 minutes, followed by 50 cycles with a temperature tran-
sition rate of 20°C/second, consisting of 95°C/second, an-
nealing at 60°C for 10 seconds, and extension at 72°C for
17 seconds. After amplification, a melting step was carried
out: 95°C/second, cooling to 45°C for 30 seconds with a
temperature transition rate of 20°C/second, and finally a
slow heating to 85°C at a rate of 0.1°C/second with contin-
uous acquisition of fluorescence decline. Further sequenc-
ing of six H. pylori isolates (four resistant, one sensitive and
a control strain) was done by the Bioneer Company, Korea.
4. Results
After culture of 80 biopsies, 20 H. pylori strains were
isolated (25%). All biochemical tests including Gram stain-
ing, catalase and oxidase tests confirmed H. pylori isolates.
Also, the presence of ureC gene in all 20 isolates was con-
firmed by PCR (Figure 1). Resistance to clarithromycin was
observed in 4 of 20 H. pylori isolates (21.7%) according to the
CLSI standards and by the E-test method. Resistant isolates
had MIC of > 0.5 mg/mL (Figure 2). The type of mutation in
clarithromycin resistance isolates was determined by real-
time PCR. According to Figure 3 melting temperature of
probes in susceptible isolates and H. pylori OC1096 strain,
was 57.5°C, but in resistance isolates this was 54.7°C. Also,
as mentioned before for confirmation of the real-time PCR
results, sequencing was done on PCR products of six iso-
lates in parallel. All resistant isolates in this study showed
a point mutation at A2143G based on the detected melting
temperature and sequencing. Two sequences of amplicons
were submitted to NCBI with accession No KP09939 and
KP09939.1.
Figure 1. PCR Amplification Performed With ureC Primers
H. pylori isolates (lanes 1-9), negative control (lane 10), positive control (lane 11) and
ladder (Qiagen).
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Figure 2. Antibiogram of Helicobacter pylori Isolates by the E-Test Method
5. Discussion
Helicobacter pylori, is a major cause of upper gastroin-
testinal disorders such as peptic and duodenal ulcers and
gastric cancer. About half of the world’s population is in-
fected with H. pylori (1). One of the best antibiotics that
are used in first line therapy for this infection is clar-
ithromycin.
Clarithromycin is a macrolide antibiotic that inhibits
protein synthesis of bacteria by binding to the 50 second
subunit of bacterial ribosome and preventing of peptidyl
transferase activity (21). However, emerging and spread-
ing of antibiotic resistance, especially resistance to clar-
ithromycin, decreases the efficacy of H. pylori infection
treatment (22). Therefore, detection of the local antibi-
otic resistance profile is important. In our study we used
the E-test method for determination of resistance to clar-
ithromycin among H. pylori isolates.
Clarithromycin resistance was observed in four of 20
H. pylori isolates (21.7%). Because of high precision and re-
producibility of E-test results, we used this method in our
study. Similar to our results, the rate of clarithromycin re-
sistance that had been reported by Ogata et al. (23) from
Brazil and De Francesco et al. (24) from Italy by the E-test
method, was about 22.62% and 18.49%, respectively. How-
ever, the rates of clarithromycin resistance that have been
described by other studies (by the E-test method) were
Figure 3. Details of Melting Curve
A, Melting Curve shows the different melting temperatures of the 267-bp amplicon
of the 23SrRNAof the control, sensitiveandresistant isolates of H. pylori in this study;
B, details of the diagram.
different. For instance, it was 41.9% in Turkey (25), 35.6%
in Spain (26), 5.3% in Costa Rica (27) and 10.6% in Taiwan
(28). Existence of such differences is logical, because antibi-
otic susceptibility profile shows geographical variation be-
tween and within countries based on age, race, population
density and availability of antibiotics (29). Such discrep-
ancies exist between studies from different parts of Iran.
For example, Sirous et al. (30) reported that all H. pylori
strains isolated from Iran were sensitive to clarithromycin
(by the disk diffusion method). Also, clarithromycin resis-
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tance rate among H. pylori isolates in Tehran (by the disk
diffusion method) and Southern Iran (Shiraz, by the E-test
method) was inconsiderable (4.16% and 5%, respectively)
(31, 32). However, other Iranian studies showed consider-
able rate of clarithromycin resistance among H. pylori iso-
lates e.g. 16% and 17.7% in north west of Iran (Tabriz, by
the E-test and modified disk diffusion method) (33, 34), 30%
in the north (Sari, by the E-test method) (35), 32% in the
west (Ilam, by the disk diffusion method) (36) and 32.4% in
Tehran (by the agar dilution method) (37).
The difference between the rates of clarithromycin re-
sistance in studies, which have been done in different
parts of Iran may be due to time differences, use of dif-
ferent susceptibility methods, sample sizes, fresh or freeze
biopsies and incubation conditions. Over all, this study
and other studies that reported high rate of resistance
to clarithromycin among H. pylori isolates, showed that
clarithromycin resistance rate has reached alarming rates
in our country, Iran. Clarithromycin is an expensive an-
tibiotic and not commonly used in Iran, so these rates of
resistance could be related to cross-reactivity with other
macrolides. For example, Fallahi and Maleknejad (31) re-
ported that the rate of resistance to erythromycin (other
kinds of macrolide antibiotics) among H. pylori strains is
4.16%, which is equal to clarithromycin resistance rates.
Resistance to clarithromycin in H. pylori is caused by
point mutations at different locations or different base
substitutions of 23S rRNA. The most common mutations
are A2143G and A2142G, and less frequently A2142C (13). The
A2142G and A2142C mutations are associated with high-
level cross-resistance to all macrolides; also the A2143G mu-
tation is linked to high-level resistance to erythromycin
(38). In this study, we used the real-time PCR method to
determine the type of mutation in resistant isolates. First,
the 267-bp fragment of 23S rRNA was amplified by Corbett
6,000, and then the mutation was determined by melting
curve analysis. According to the melting curve Figure 3,
the melting temperature of all resistant H. pylori isolates
was at 54.7°C. Therefore, all resistant H. pylori isolates had
the A2143G mutation. Also, sequencing results confirmed
A2143G mutation. The melting temperature of suscepti-
ble and OC1096 strain, were 61ºC and 57.5º C, respectively.
Oleastro et al. (17) used the Light thermo cycler apparatus
and reported that the melting temperature of susceptible,
standard and resistance (A2143G mutation) isolates were
61.5ºC, 58ºC and 53.6ºC, respectively.
The inconsiderable difference to our results (57.6ºC)
may be due to the use of different instruments and stan-
dard strains. Sadeghifard et al. (36) investigated mu-
tations of 23S rRNA gene among H. pylori isolates by
the PCR-restriction fragment length polymorphism (RFLP)
method. In that study, all resistant isolates had the A2143G
mutation. Also, in a study performed by Kargar et al.
(39) using PCR-RFLP, mutation of A2143G was the dominant
point mutation among H. pylori isolates. Mohammadi et
al. (40) used the PCR-RFLP method and reported 73.68%
of H. pylori isolates had the A2143G mutation. All men-
tioned studies reported similar point mutations among
Iranian H. pylori strains despite the use of different meth-
ods. Therefore, it seems that the frequency of A2143G muta-
tion among clarithromycin resistant H. pylori isolates from
Iranian patients is higher than other mutations. Similar
results were observed in clarithromycin-resistant H. pylori
strains isolated from Korea (by PCR amplification and nu-
cleotide sequence analyses) (41), Argentina (by PCR-RFLP
method) (42) and Colombia (by the PCR-RFLP method) (43).
However, other kinds of point mutations of clarithromycin
resistance were shown in other studies from Iran. For ex-
ample, the incidence of A2142G genotype in the study of
Naserpour Farivar et al. (44), by scorpion real-time PCR,
was higher than other mutations. Also, in the study of
Khademi et al. (45) all clarithromycin-resistant H. pylori iso-
lates had the T2243C mutation by PCR and further sequenc-
ing methods.
In conclusion, our results and other studies in Iran,
despite some controversial results, showed that the rate
of clarithromycin resistance is increasing in our country.
Also it seems the most popular pattern of clarithromycin
resistance among Iranian H. pylori isolates is the A2143G
mutation. Also determination of the antibiotic resistance
profile and finding alternative treatment regimens in any
region of the world is necessary. Finally, real-time PCR is a
rapid and reproducible method for detecting mutations in
23S rRNA of H. pylori isolates. For better evaluation of clar-
ithromycin resistance rate and finding the predominant
molecular pattern of resistance among Iranian H. pylori iso-
lates, doing such study with a greater sample size is recom-
mended.
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